# DB-1305 / BNT325

Source: https://onco.cc/drugs/db-1305/  
OnCo record `db-1305` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DB-1305 / BNT325 is an experimental antibody-drug conjugate being studied in people with advanced cancer. Its benefit and safety are still being evaluated.

## Summary

SABCS 2025 abstract PS5-02-29 reports 26 previously treated metastatic TNBC patients at the March 31, 2025 cutoff. Prior sacituzumab govitecan was excluded. Median follow-up was 9.3 months; grade 3 or higher treatment-related adverse events occurred in 9/26 patients (34.6%) and one discontinued for anemia. The deposited abstract does not provide its referenced efficacy table, so a response rate is not inferred. This uncontrolled cohort cannot rank DB-1305 against approved ADCs.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-10-06
- Modality: ADC
- Mechanism: TROP2-directed antibody-drug conjugate with a cleavable linker and a topoisomerase I inhibitor.
- Payload: TOP1 inhibitor

## Sources

- Publisher abstract: https://doi.org/10.1158/1557-3265.sabcs25-ps5-02-29
- ClinicalTrials.gov NCT05438329: https://clinicaltrials.gov/study/NCT05438329

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- trials: [DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct06953089/), [First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors](https://onco.cc/trials/nct05438329/)

---
JSON: https://onco.cc/api/v1/entities/db-1305.json